Dr. Amit Kumar

Chemical and Biomolecular Engineering

Personal Bio

Amit Kumar is a Postdoctoral Research Associate at St Jude Children's Research Hospital. He received his Ph.D. in Chemical and Biomolecular Engineering from JHU at Dr. Michael Betenbaugh's lab and B.Tech. in Chemical Engineering from Indian Institute of Technology Madras. He has been active in the area of recombinant protein production and expression for over 6 years. He has worked extensively on integrating systems biology with metabolic engineering and has used OMICS techniques to identify and increase the quantity and quality of recombinant protein production in mammalian cell lines.

Education History

  • B.Tech. (Bachelor of Technology) Chemical Engineering, Indian Institute of Technology Madras
  • PHD Chemical & Biomolecular Engineering, Johns Hopkins University

Work Experience

Post Doctoral Associate, St. Jude Children's Research Hospital

Publications

[1] Kumar A, Baycin-Hizal D, Zhang Yue, Bowen Michael, Betenbaugh MJ (2015), “Cellular traffic cops: the interplay between lipids and proteins regulates vesicular formation, trafficking, and signaling in mammalian cells”, doi: 10.1016/j.copbio.2015.09.006

[2] Kumar A, Baycin-Hizal D, Wolozny D, Pedersen LE, Lewis NE, Heffner K, Chaerkady R, Cole RN, Shiloach J, Zhang H, Bowen MA, Betenbaugh MJ (2015), “Elucidation of the CHO Super-Ome (CHO-SO) by Proteoinformatics”, doi: 10.1021/acs.jproteome.5b00588

[3] Kumar A, Shiloach J, Betenbaugh MJ, Gallagher EJ (2015). “The beta-3 adrenergic agonist (CL-316,243) restores the expression of down-regulated fatty acid oxidation genes in Type 2 diabetic mice”, Nutr Metab, 2015, 12:8, doi:10.1186/s12986-015-0003-8

[4] Kumar A, Baycin-Hizal D, Shiloach J, Bowen M, Betenbaugh MJ (2014). “Coupling Enrichment and Proteomics Methods for Understanding and Treating Disease”, Proteomics Clin Appl., Dec 19, doi: 10.1002/prca.201400097

[5] Kumar A, Heffner K, Shiloach J, Betenbaugh MJ, Baycin-Hizal D (2014). “Harnessing proteomics to characterize CHO cell physiology”, Pharmaceutical Bioprocessing, 2(5), 421–435, 10.4155/PBP.14.49

[6] Kumar A, Harrelson T, Lewis NE, Gallagher EJ, LeRoith D, Shiloach J, Betenbaugh MJ (2014) “Multi-Tissue Computational Modeling Analyzes Pathophysiology of Type 2 Diabetes in MKR Mice.” PLoS ONE 9(7): e102319. doi: 10.1371/journal.pone.0102319

[7] Heffner K, Kumar A, Kaas C, Baycin-Hizal D, Betenbaugh MJ (2014). “Proteomics in Cell Culture: From genomics to combined ‘omics for cell line engineering and bioprocess development”, Cell Engineering: Animal Cell Culture, Al Rubeai M. (editor), Springer, doi: 10.1007/978-3-319-10320-4

[8] Heffner K, Baycin-Hizal D, Kumar A, Zhu J, Bowen M, Shiloach J, Betenbaugh MJ (2014). “Exploiting the proteomics revolution in biotechnology: from disease and antibody targets to optimizing bioprocess development”, Current Opinion in Biotechnology 30: Pharmaceutical biotechnology, Dec;30:80-6, doi: 10.1016/j.copbio.2014.06.006.

[9] Baycin-Hizal D, Tabb DL, Chaerkady R, Chen L, Lewis N, Nagarajan H, Sarkaria V, Kumar A, Wolozny D, Colao J, Jacobson E, Tian Y, O’Malley RN, Krag S, Cole RN, Palsson BO, Zhang H, Betenbaugh MJ (2012), “Proteomic Analysis of Chinese Hamster Ovary (CHO) Cells”, Proteome Res., Nov 2;11(11):5265-76. doi: 10.1021/pr300476w.

Professional Organizations

None